Olatunji Alese MD
- Department of Hematology and Medical Oncology
Associate Professor
- (404) 778-6639
- olatunji.alese@emory.edu
Overview
A board certified medical oncologist, Dr. Alese specializes in the treatment of gastrointestinal cancers, particularly colorectal cancer. He joined the clinical staff at Winship Cancer Institute as a practicing physician in July 2015.<br /><br />Dr. Alese serves as director of gastrointestinal oncology at Winship Cancer Institute of Emory University.<br /><br />Dr. Alese is a member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He previously served on the Advisory Group of ASCO International Affairs Committee, and he is a member of several professional organizations.<br /><br />Dr. Alese received his MD from University of Ibadan, Nigeria in 2000. His postgraduate medical education included residency training at University College Hospital in Nigeria and New York Medical College - Metropolitan Hospital Center. He completed his fellowship in hematology/oncology at Winship Cancer Institute of Emory University.<br /><br />Dr. Alese's research focuses on colorectal cancer and health disparities.<br /><br />Dr. Alese has several awards including the American Society of Clinical Oncology (ASCO) International Development and Education Award (IDEA), and ECOG Foundation/Paul Carbone, MD Fellowship award. A previous German Academic Exchange Service (DAAD) scholar, his additional distinctions and awards include University of Ibadan Skilled Hands Award, UICC International Cancer Technology Transfer Fellowship, European Society for Medical Oncology (ESMO) TRU Visit Grant, and 2014 ASCO Merit award.
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from University of Ibadan, Ibadan
Research
Publications
-
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.
Oncoimmunology Volume: 14 Page(s): 2475620
12/01/2025 Authors: Phillips MJ; Alese OB; Horvat NK; Greene E; Gbolahan OB; Coleman K; Doxie DB; Parihar V; Mahdi ZK; McCook-Veal A -
ASO Author Reflections: The Evolving Role of Immunotherapy for Gastro-Esophageal Malignancies.
Ann Surg Oncol Volume: 32 Page(s): 6907 - 6908
09/01/2025 Authors: Emiloju O; Miao R; Alese O -
The Evolving Role of Immunotherapy for Gastroesophageal Malignancies.
Ann Surg Oncol Volume: 32 Page(s): 6884 - 6901
09/01/2025 Authors: Emiloju O; Miao R; Alese O -
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
J Hepatol
08/12/2025 Authors: Meyer T; Finn RS; Borad M; Mahipal A; Edeline J; Houot R; Hausner PF; Hollebecque A; Goyal L; Frigault M -
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
J Clin Oncol Page(s): JCO2500363
07/24/2025 Authors: Wermke M; Gambardella V; Kuboki Y; Felip E; Sanmamed MF; Alese OB; Sayehli CM; Arriola E; Wolf J; Villaruz LC -
Utilizing Patient Input in Rectal Cancer Trial Design.
J Natl Cancer Inst Volume: 117 Page(s): 1421 - 1428
07/01/2025 Authors: Alvarez J; Zambare W; George M; Garcia R; Gallagher P; Kitchens C; Bercz A; Kim MJ; Romesser PB; Cercek A -
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine.
Cell Rep Med Volume: 6 Page(s): 101881
01/21/2025 Authors: Nagaraju GP; Saddala MS; Foote JB; Khaliq AM; Masood A; Golivi Y; Bandi DSR; Sarvesh S; Reddy SP; Switchenko J -
Dosing matters: DESTINY-CRC02 and the evolving treatment paradigm for HER2 positive colorectal cancer.
Transl Gastroenterol Hepatol Volume: 10 Page(s): 36
01/01/2025 Authors: Hannan LM; Alese OB -
The role of UGT1A1 polymorphism in the management of colorectal cancer.
Oncol Rev Volume: 19 Page(s): 1547904
01/01/2025 Authors: Babadi E; Roudini K; Aalipour K; Alese OB -
Perceptions and Needs for a Technology-Based Dyadic Intervention on Symptom Management Among Patients With Colorectal Cancer and Their Caregivers: A Qualitative Study.
Cancer Nurs
11/29/2024 Authors: Epari A; Kim K; Xiao C; Porter LS; Alese OB; Northouse L; Liu D; Graetz I; Lin Y